Request Demo
Blackstone unearths Uniquity Bio with $300M to explore Merck drug's I&I potential
AcquisitionIPOImmunotherapyDrug ApprovalADC
Uniquity Bio unveiled with full financial backing from Blackstone Life Sciences.
Uniquity Bioto be launching a new biotech focused on inBlackstone Life Sciencesy.
Uniquity Bio is the latest such company, unveiled by inflammationife Sciences on Wednesday with $300 million and a phase 2-stage lead asset. Solrikitug, an anti-TSLP antibody in-licensed from Merck & Co., was just given the green light by the FDA for two looming studies in chronic obstructive pulmonary disease (COPD) and asthma, respectively. And Blackstone’s head of life science investments suggests the pipeline may soon grow.
Uniquity Biod to partner with Uniquity’s team of veteBlackstone Life Sciencesthey advance solrikitug and expand their immunology and inflammaSolrikitugine wanti-TSLP antibodygrams in the near Merck & Co.cholas Galakatos, Ph.D., said in a releaFDAchronic obstructive pulmonary disease (COPD)asthmaBlackstone
Consider this announcement a bUniquityl to the companies that missed out on the Aiolos Biosolrikituges. That biotech similarly launchinflammation than $200 million in October 2023 with an anti-TSLP antibody and less than three months later, GSK came calling, buying the company for $1 billion with $400 million in milestone payments up for grabs.
Uniquity touts solrikitug as a “highly potent” TSLP receptor binder, with possibAiolos Biotion in a wide range of immunology and inflammation conditions. If successful, the company believeanti-TSLP antibodyt in an increasingly crowded marketGSKniquity expects the space to balloon more than 150% by 2032, with pharmas and new entrants alike seeking an opportunity to challenge AstraZeneca and Amgen’s anti-TSLP asthma med Tezspire.
Uniquity is thesolrikitug a series of seismic pTSLP receptor binderTSLP receptoring rounds backing I&I companies. In the past week alone, Attovia Theinflammationunched with $105 million to treat itch conditions and Zenas added $200 million in series C capital forUniquityoimmune drug, obexelimab. In late March, the former leader of Merck-bought Prometheus launched Mirador Therapeutics with $400 AstraZenecaAmgenTSLP asthma
Uniquityquity has entered the fold with the backing of Blackstone’s full purse.Attovia TherapeuticsitchZenasZenasobexelimabMerckPrometheusMirador Therapeutics
“We’rUniquityd about the work that Uniquity has done soBlackstonesolrikitug and look forward to providing long-term financial support to the company,” Senior Managing Director Kiran Reddy, M.D., said in this morning's announcement.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.